Home | MDS Hub

All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Steering Committee About Us Newsletter Contact

Visit:

Steering Committee About Us Newsletter Contact

Types Therapeutics Congresses Trials Expert Opinions

MDS Types

EHA2021 practice-changing abstracts in myelodysplastic syndromes

World-leading experts in MDS shared the top abstracts from the EHA2021 Virtual Congress that they believed could have the greatest impact on clinical practice.

Jul 21, 2021

|EHA 2021

How can the hematologic toxicities with Ven+Aza be managed more effectively?

During the 2021 ASCO Annual Meeting, the MDS Hub spoke with Jacqueline S. Garcia, Dana-Farber Cancer Institute, Boston, US, and Amer M. Zeidan, Yale School of Medicine, New...

Jul 8, 2021

|ASCO 2021

Hot off the press | Understanding patient’s burden, quality of life, and alignment of patient-reported outcome measures to capture changes in high-risk MDS/AML

Treatment considerations regarding the quality of life (QoL) impact for patients with...

Jul 7, 2021

Prevalence and impact of PPM1D mutations in patients with MDS and del(5q)

Mutations in the PPM1D gene drive clonal hematopoiesis and occur in various malignancies.

Jul 5, 2021

|MDS-del(5q)

Theo de Witte

"The MDS Hub allows you to access the most relevant updates in myelodysplastic syndromes and related disorders. We aim to deliver valuable and up-to-date information and expert opinions to all physicians practicing hemato-oncology."

Featured Expert Opinion

How does COVID-19 infection affect hematopoiesis in MDS?

During the ESH 2nd Translational Research Conference: Erythropoiesis Control and Ineffective Erythropoiesis - From Bench to...

ESH 7th Translational Research E-Conference: Myelodysplastic Syndromes

What is new for MDS with del(5q)?

During the7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to María Díez Campelo,...

Mar 17, 2021

|ESH 2021

What are novel strategies to treat low-risk MDS?

During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Uwe...

Feb 20, 2021

|ESH 2021

Is there a place for immunotherapy in MDS?

During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Shahram Kordasti,...

Feb 16, 2021

|ESH 2021

What are novel strategies to treat higher-risk MDS?

During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Mikkael...

Feb 16, 2021

|ESH 2021

Risk

How can the hematologic toxicities with Ven+Aza be managed more effectively?

During the 2021 ASCO Annual Meeting, the MDS Hub spoke with Jacqueline S. Garcia, Dana-Farber Cancer Institute, Boston, US,...

Jul 8, 2021

|ASCO 2021

What hematologic toxicities occur after venetoclax + azacitidine in MDS and how can they be managed?

During the EHA2021 Virtual Congress, the MDS Hub spoke with Uwe Platzbecker, University of Leipzig...

Jun 30, 2021

|EHA 2021

Will luspatercept become the new treatment standard after ESA failure in RS-positive LR-MDS patients with TD anemia?

Erythropoiesis-stimulating agents (ESAs) are the standard first-line treatment for...

Jun 21, 2021

|Lower-risk

The use of whole-genome sequencing as an alternative diagnostic tool for cytogenetic analysis in myeloid cancers

The use of whole-genome sequencing as an alternative diagnostic tool for cytogenetic...

Jun 18, 2021

|Risk

MDS-related mutations

Prevalence and impact of PPM1D mutations in patients with MDS and del(5q)

Mutations in the PPM1D gene drive clonal hematopoiesis and occur in various malignancies.

Jul 5, 2021

|MDS-del(5q)

How should molecular profiling be used to guide MDS therapy?

During the Acute Leukemia Forum (ALF) 2021, the MDS Hub spoke to Rafael Bejar, UC San Diego, San Diego, US. We asked, How should molecular...

Apr 23, 2021

|ALF 2021

Germline mutations in patients with hematologic malignancies

Germline mutations in patients with neoplasms are more common than expected and have been found not only in children but also adults with...

Apr 21, 2021

|MDS

Editorial theme | Immune dysregulation and genetic mutations associated with MDS pathogenesis

The pathogenesis of myelodysplastic syndromes (MDS) is heterogeneous, involving inflammation, cytokines,...

Mar 24, 2021

|MDS-related mutations

Most Viewed

Highlights of EHA 2021

What baseline factors affect QoL in MDS? How do these change with treatment?

Which subgroups of patients benefit most from a Ven+Aza combination?

How can cytogenetics predict response to venetoclax and azacitidine in MDS?

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

EHA2021 practice-changing abstracts in myelodysplastic syndromes

Jul 21, 2021

|EHA 2021

Jul 8, 2021

|ASCO 2021

Jul 7, 2021

Jul 5, 2021

|MDS-del(5q)

Theo de Witte

ESH 7th Translational Research E-Conference: Myelodysplastic Syndromes

Mar 17, 2021

|ESH 2021

Feb 20, 2021

|ESH 2021

Feb 16, 2021

|ESH 2021

Feb 16, 2021

|ESH 2021

Risk

Jul 8, 2021

|ASCO 2021

Jun 30, 2021

|EHA 2021

Jun 21, 2021

|Lower-risk

Jun 18, 2021

|Risk

Most Read

MDS-related mutations

Jul 5, 2021

|MDS-del(5q)

Apr 23, 2021

|ALF 2021

Apr 21, 2021

|MDS

Mar 24, 2021

|MDS-related mutations

Most Viewed